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Prognosis of Hospitalized New-Onset Systolic Heart Failure
in Indo-AsiansdA Lethal Problem
FAHIM H. JAFARY, MD, FACC, MAHESH KUMAR, MD, AND IRFAN E. CHANDNA, MD
Karachi, Pakistan
ABSTRACT
Background: Systolic heart failure (SHF), particularly when requiring hospital admission carries a poor
prognosis. There is a paucity of data in Indo-Asians on outcomes of SHF, among whom the burden of
cardiovascular disease is consistently rising. The purpose of this study was to determine the frequency
and predictors of mortality and morbidity amongst patients admitted with new-onset SHF at a tertiary
care hospital in Pakistan.
Methods and Results: Hospital charts of 196 patients with a diagnosis of new or recent onset (!3
months) SHF (ejection fraction [EF] !40%) were reviewed. Patients who died during the admission,
those with life-limiting concomitant disease, and those without follow-up were excluded. Survival was cal-
culated according to the Kaplan-Meier method. Hazards ratios (HR) and 95% confidence intervals (CI)
were calculated using Cox’s regression model. Mean age (SD) was 61 (12.8) years. Majority (77%)
had a prior ischemic heart disease. Mean EF (SD) was 25% (8.7). Median follow-up period was 379
days. Fifty-four (27.5%) patients died (at least 12 [22.2%] sudden deaths) and 102 (52%) experienced
combined event of death or repeat hospitalization for SHF. Factors independently associated with death
included (HR [95% CI]), serum sodium (0.94 [0.90e0.97]), admission pulse (1.02 [1.01e1.04]), systolic
blood pressure (0.98 [0.97e0.99]), and severe mitral regurgitation (1.90 [1.03e3.48]).
Conclusions: Admission for new or recent onset SHF predicts a grave 1-year prognosis in Indo-Asians.
Measures to prevent ischemic heart disease and its sequelae are essential because developing nations sim-
ply cannot afford to treat and manage heart failure. (J Cardiac Fail 2007;13:855e860)
Key Words: Heart failure, systolic dysfunction, congestive heart failure, left ventricular dysfunction,
developing country.
Congestive heart failure has become an increasingly fre-
quent cause of hospital admission over the last 20 years.1
Heart failure from systolic dysfunction carries a highly ad-
verse prognosis despite significant advancements in ther-
apy. The 1-year mortality of systolic heart failure in the
era of modern heart failure therapy (1990s and beyond) is
reported to be 28% in men and 24% in women.2 These es-
timates include all-comers with systolic heart failure and do
not make a distinction between those with chronic heart
failure and those who experience a heart failureerelated
hospitalization. Hospitalized heart failure is widely re-
garded as prognostically more adverse with a high mortality
and readmission rate.3 There is a paucity of data on out-
comes of heart failure in general and hospitalized heart fail-
ure in particular in Indo-Asians. We sought to determine the
1-year morbidity and mortality among patients admitted
with new-onset heart failure from systolic dysfunction at
a tertiary care hospital in Pakistan. We also endeavored to




This was a retrospective cohort study conducted at the Aga
Khan University Hospital in Karachi, Pakistan. The Aga Khan
University Hospital is a tertiary care hospital located in the metro-
politan city of Karachi and receives a mixture of affluent and low-
and middle-income patients and serves the entire city as a referral
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center for patients requiring high-intensity tertiary care. The hos-
pital medical records follow the ICD-9 coding system. Hospital
medical records from January 2002 to December 2003 were
searched using terms ‘‘heart failure,’’ ‘‘congestive heart failure,’’
‘‘systolic dysfunction,’’ and ‘‘left ventricular dysfunction.’’ Pa-
tients were included in this study if they met the following criteria
for new-onset admitted systolic heart failure: (1) first presentation
to the hospital with the diagnosis of congestive heart failure that
met the Boston criteria,4 (2) no prior diagnosis of heart failure
or recently diagnosed with systolic heart failure within the last 3
months. Systolic dysfunction was defined as an estimated left ven-
tricular ejection fraction (LVEF) of! 40% by echocardiography,
gated single-photon emission computed tomography imaging or
left ventricular angiography. Patients were excluded if (1) LVEF
was $40%, (2) there was a prior diagnosis of systolic heart failure
dating back O3 months, (3) they had an underlying disease with
expected survival!6 months, (4) they had known primary valvu-
lar heart disease, whether rheumatic or nonrheumatic, (5) the pa-
tient died in-hospital, and (6) no follow-up was available after
discharge.
Data Collection
Hospital charts of 700 patients with a discharge diagnosis of
congestive heart failure were screened, of which 220 met inclusion
criteria. Reasons for exclusions were as follows: established diag-
nosis of systolic heart failure (232), heart failure with preserved
systolic function (113), malignancy (25), known valvular heart
disease (73), and in-hospital death, mostly from comorbid condi-
tions (eg, sepsis with concomitant [often secondary] systolic dys-
function [37]). Complete data were available for 196 patients.
Variables recorded included age, sex, history of diabetes mellitus
(defined as a fasting glucose $126 mg/dL or on treatment), hyper-
lipidemia (fasting cholesterol $200 mg/dL or on treatment), hy-
pertension (systolic blood pressure $140/90 mm Hg or on
treatment), smoking (ever versus never), prior percutaneous coro-
nary intervention or coronary artery bypass grafting, prior treat-
ment, admission systolic and diastolic blood pressure, pulse,
admission laboratory data including white blood cell count, serum
creatinine, sodium and hemoglobin, estimate of LVEF by gated
single-photon emission computed tomography imaging or left
ventricular angiography (if available), QRS width on admission
electrocardiogram (estimated manually from the beginning of
the first ventricular depolarization to the end of the QRS complex,
recorded in millisecondsda wide QRS was defined as a width
O120 ms), and echocardiographic data including dimensions, es-
timated LVEF, and presence of valvular regurgitation. Echocardio-
graphic data were acquired by experienced technicians as part of
routine clinical care. LV dilation was defined as an LV end-dia-
stolic dimension ofO55 mm. Hyponatremia was defined as a se-
rum sodium !135 mmol/L. Follow-up information was recorded
from the hospital records and then further refined by contacting
patients (or family members) by telephone to document out of
hospital mortality events or hospitalizations at other institutions.
Cardiac mortality was defined as death from documented (or re-
ported) myocardial infarction, heart failure, or sudden death. Sud-
den cardiac death was defined as recommended by the recent
American Heart Association scientific statement.5 The primary
outcome variable was cardiac mortality. The secondary outcome
variable was a combination of cardiac death or readmission for
congestive heart failure. Only the first hospitalization was consid-
ered for this analysis.
Statistical Methods
All variables were entered into Statistical Package for Social
Sciences version 14 (SPSS Inc, Chicago, Illinois, USA). Means
and standard deviations were calculated for continuous variables
and frequencies for categorical variables. Univariate survival anal-
ysis was performed according to the Kaplan-Meier method and
differences in survival curves were assessed with the log-rank
test. Patients lost at follow-up or dying from noncardiovascular
causes were censored at the time of the last visit or contact. Poten-
tial survival correlates were further scrutinized with univariate and
multivariate Cox proportional hazards models, with calculated risk
ratios (HR) for independent variables reported with 95% CI. Vari-
ables with a p value of #0.2 were entered into the multivariable
model. The number of variables considered was intentionally
limited because of the relatively small sample size. In a visual
evaluation of log(elog(survival)) plots no violation of the propor-
tional hazards assumption became apparent. P values! .05 were
considered significant. Censored individuals who were lost to fol-
low-up were compared with respect to baseline characteristics to
the remaining cohort no significant differences were apparent,
thus no violation of the censoring assumptions was noted. Survival
curves were plotted using SPSS 14. The authors had full access to
the data and take responsibility for its integrity. All authors have
read and agree to the manuscript as written.
Results
A total of 196 patients were included in this study. Table 1
shows the baseline characteristics of the study cohort. The
mean age was approximately 61 years and with a high pre-
ponderance of males. This was a relatively unhealthy group
of patients with more than 60% suffering from hypertension
and diabetes mellitus and more than three-fourths having
a history of coronary artery disease in the past. Mean ejec-
tion fraction was 25% and, consistent with the selection of
new-onset cases, only a minority were on renin-angiotensin
blocking agents (angiotensin-converting enzyme inhibitor
or angiotensin receptor blocker) before admission. Surpris-
ingly, despite a previous history of coronary artery disease,
only 13% were on b-blockers before presentation.
The median (interquartile range) follow-up time was 379
(211 to 500) days, respectively. After discharge from the
hospital, a high event rate was observed in this cohort. A
total of 54 patients (27.5%) died, of which 50 (92.5%)
were cardiovascular in origin. Of these, at least 12
(22.2%) died suddenly. Seventy-three patients (37.2%) re-
quired rehospitalization for congestive heart failure. The
combined event (death or hospitalization for heart failure)
occurred in 102 patients (52%) over this follow-up period
(median event-free survival of 324 days).
Figure 1 shows the Kaplan-Meier curves for the overall
survival experience of the cohort in terms of the primary
and combined endpoints. As can be seen, there is a steady
increase in the cumulative incidence of events with time.
Table 2 shows the univariate predictors of mortality in
our cohort. On univariate analysis, admission pulse, systolic
blood pressure, serum sodium, and b-blockers at discharge
were significantly associated with mortality. Trends of
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association with mortality were noted with severe mitral re-
gurgitation (versus no severe regurgitation), low pulse pres-
sure (!40 mm Hg), anemia (hemoglobin !10 g/dL), and
elevation of serum troponin. On Cox proportional hazards
multivariate regression (Table 3), serum sodium, admission
systolic blood pressure, pulse on admission, and severe mi-
tral regurgitation were significantly associated with mortal-
ity after discharge. The only independent predictor for the
combined end point was discharge on renin-angiotensin
blocking agents (HR 0.60 [95% CI 0.37e0.97]; P 5 .037).
Discussion
This is the first study from the Indo-Pakistan subconti-
nent, home to one-sixth of the world’s population,
describing the patient characteristics and clinical outcomes
of patients requiring admission for systolic heart failure.
We describe a high mortality and morbidity over a median
follow-up of less than 1 year with nearly a quarter dying
and more than half experiencing the combined end point
of death or hospitalization for heart failure. Independent
correlates of mortality in our cohort included serum so-
dium, systolic blood pressure, and pulse on admission and
severe mitral regurgitation on echocardiography.
There are several possible reasons for the high mortality
and morbidity noted in our study. First, as seen in Table 1,
the study group is a fairly unhealthy population with a ma-
jority suffering from diabetes mellitus, hypertension, and
previous coronary artery disease. Second, by design, our
study looked at patients with systolic dysfunction who re-
quired admission. This group of heart failure patients is in-
herently high risk. Earlier studies suggested a very high
mortality of hospitalized heart failure.6,7 These studies
were published in the days prior to routine initiation of
angiotensin-converting enzyme inhibitor therapy in heart
failure. More recently, Roguin and colleagues8 described
a nearly 40% 1-year mortality in patients discharged after
acute heart failure. Shahar and colleagues analyzed a large
database of heart failure admissions spanning more than 22
hospitals and reported a 1-year mortality of more than
30%.9 Almost identically, Lee et al reported a 32.9% a 1-
year mortality in more than 4000 community-based Cana-
dian patients admitted for heart failure.10 These studies
were more heterogenous in that they included patients
with prior diagnoses of heart failure, many of whom were
Table 1. Baseline Characteristics of Patients with New-
Onset Systolic Heart Failure Admitted to a Tertiary Care
Hospital in Pakistan (n 5 196)
Baseline Characteristics n
Age (mean [SD]) 61.2 (12.8)
Male 127 (64.8)
Signs and symptoms
Dyspnea at rest 177 (90.3)
Orthopnea 145 (74.0)
Dyspnea on mild exertion 19 (9.7)
Pulse (mean [SD]) 97 (22)
Pulse O100/min 73 (37.2)
SBP (mean [SD]) mm Hg 131.9 (30.1)
DBP (mean [SD]) mm Hg 79.3 (19.0)
SBP !100 mm Hg 28 (14.4)
Mean arteria pressure (mean [SD]) mm Hg 96.9 (21.3)
Jugular venous distension 112 (57.1)
Rales on examination 164 (83.7)
Third heart sound 42 (21.4)
Pedal edema 14 (7.1)
Pulmonary edema on chest radiograph 179 (91.3)
Hypertension 132 (67.3)
Diabetes mellitus 119 (60.7)
Smoking 59 (30.1)
Prior CAD* 150 (76.5)
Hyperlipidemia 81 (41.3)
Prior ACEI/ARB therapy 15 (7.7)
Prior b-blocker therapy 25 (12.8)
Troponin elevationy 46 (27.7)
EF (mean [SD]) 25 (8.6)
Dilated LVz 77 (43.8)
Severe mitral regurgitation 60 (30.6)
Creatinine (mean [SD]) mg/dL 1.7 (1.4)
QRS wide (O 120 ms) 35 (19.3)
Serum sodium (mean [SD]) mmol/L 133.9 (6.4)
Hyponatremiax 98 (50.0)
Discharge medications
ACEI or ARB 164 (83.7)
b-blockers 118 (60.2)
Aspirin 160 (81.6)
Parentheses indicate percentages unless otherwise stated. SD, standard
deviation; SBP, systolic blood pressure; CAD, coronary artery disease;
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin recep-
tor blockers; EF, ejection fraction; LV, left ventricle.
*Defined as prior history of documented infarction, ischemia on stress
test, or disease on angiography.
yDefined as O1.0 ng/mL.
zDefined as left ventricular end diastolic dimension O55 mm; missing
data in 20 patients.
xNa !135 mmol/L.
Fig. 1. Cumulative incidence of death and combined end point of
death or hospitalization for heart failure in patients with new onset
systolic heart failure admitted to a tertiary care hospital in Paki-
stan (n 5 196). Ticks on cumulative incidence curves represent
censored events. Vertical bars represent 95% confidence limits
of the estimated proportion suffering end points at time intervals
of 200 and 400 days in each curve.
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already on angiotensin-converting enzyme inhibitors/angio-
tensin receptor blockers or b-blocker therapy; therefore,
their hospitalization represents failure of therapy (and
thus higher risk). However, a recent population-based study
by Cowie et al in patients with new heart failure referred
from general practitioner offices for acute admission had
a dismal prognosis: the 1-year survival rate was only
62%. Our study limited itself to new-onset systolic heart
failure and also reports a high mortality in the first year af-
ter discharge, emphasizing that hospitalization for systolic
heart failure marks a highly adverse prognosis. Third,
ours being a referral center may have attracted high-risk pa-
tients, leading to the high event rate. Our selection of new
cases would be expected to reduce the effect of this bias.
However, it is also possible that many of the so called
‘‘new-onset’’ failure patients were simply patients with an
established (but undiagnosed) problem who eventually pre-
sented to the hospital when their conditioned worsened.
Thus paradoxically, they may have been high-risk subjects.
Our findings of a strong association between serum so-
dium, systolic blood pressure, and pulse with mortality
are consistent with reported data, including the Heart Fail-
ure Survival Score and Seattle Heart Failure Model11,12 as
well as a recent Canadian study in which patients had
very similar characteristics.10 Hyponatremia is a marker
of neurohormonal activation, particularly rennin, and has
consistently been associated with adverse outcomes.13
Tachycardia reflects activation of the sympathetic neurohor-
monal system and is also associated with poor outcomes.14
Likewise, low blood pressure inherently reflects severity of
disease and, not surprisingly, has been associated with
Table 2. Univariate Predictors of Survival in Patients Admitted With New-Onset Systolic Heart Failure at a Tertiary Care Hospital in
Pakistan (n 5 196)
Survived (n 5 146) Died (n 5 50) Unadjusted HR (95% CI) P Value
Age (mean [SD]) 61.3 (11.7) 60.8 (15.7) 1.00 (0.97e1.02) .681
Male sex 97 (66.4) 30 (60.0) 1.00 (0.97e1.02) .681
Diabetes mellitus 89 (61.0) 30 (60.0) 0.96 (0.54e1.69) .880
Hypertension 101 (69.2) 31 (62.0) 0.73 (0.41e1.30) .287
Smoking 47 (32.2) 12 (24.0) 0.67 (0.35e1.30) .234
Troponin elevationx 31 (24.6) 15 (37.5) 1.71 (0.90e3.24) .103
EF (mean [SD]) 24.9 (8.4) 22.9 (8.3) 0.97 (0.94e1.01) .141
LV dilationx 56 (43.4) 21 (47.0) 1.00 (0.56e1.78) .996
Severe MR* 40 (27.4) 20 (40.0) 1.70 (0.97e3.00) .066
Diastolic dysfunction 91 (62.3) 33 (66.0) 1.16 (0.65e2.10) .617
Renal insufficiencyz 44 (30.1) 14 (28.0) 0.97 (0.52e1.83) .934
PASP (mean [SD]) 50.5 (13.1) 51.4 (14.0) 1.01 (0.98e1.04) .545
QRS wide (O120 ms) 25 (17.1) 10 (20.0) 1.14 (0.57e2.30) .715
Hemoglobin (mean [SD]) g/dL 12.3 (2.0) 12.1 (2.1) 0.94 (0.83e1.08) .397
Anemia (Hb ! 10 g/dL) 19 (13.3) 9 (18.0) 1.52 (0.74e3.12) .259
SBP (mean [SD]) mm Hg 134.9 (30.9) 122.8 (25.8) 0.98 (0.97e0.99) .008
SBP ! 100 mm Hg 17 (11.6) 11 (22.0) 2.05 (1.05e4.01) .037
Low pulse pressure (!40 mm Hg) 24 (16.6) 13 (26.0) 1.74 (0.92e3.27) .089
Pulse (mean [SD]) beats/min 95.4 (21.6) 103 (22.7) 1.01 (1.00e1.02) .042
Pulse O100/min 48 (32.9) 25 (50.0) 1.82 (1.04e3.16) .035
Sodium (mean [SD]) mmol/L 134.8 (5.7) 131.1 (7.5) 0.93 (0.90e0.97) !.001
Hyponatremia (!135 mmol/L) 65 (44.5) 33 (60.0) 2.28 (1.27e4.11) .005
b-blockers at discharge 95 (65.1) 23 (46.0) 0.49 (0.28e0.85) .012
ACEI/ARB at discharge 124 (84.9) 40 (80.0) 0.66 (0.33e1.32) .233
Ischemic CMPy 110 (75.3) 41 (80.0) 1.26 (0.63e2.51) .511
Parentheses in first two columns indicate percentages unless otherwise stated. HR, hazards ratio; CI, confidence interval; SD, standard deviation; CAD,
coronary artery disease; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EF, ejection fraction; LV, left ventricular; MR,
mitral regurgitation; PASP, pulmonary artery systolic pressure; Hb, hemoglobin; Hg, mercury; CMP, cardiomyopathy.
*Versus no severe MR.
zCreatinine O1.5 mg/dL.
yDefined as history of prior documented MI, prior coronary revascularization (coronary artery bypass graft or percutaneous coronary intervention) or
known CAD by prior angiography or positive functional study (echocardiographic or nuclear) or elevation of cardiac troponin during present admission
O1 ng/mL.
xMissing data.
Table 3. Cox Proportional Hazards Model Showing
Multivariate Predictors of Mortality in Patients Admitted
With New-Onset Systolic Heart Failure at a Tertiary Care
Hospital in Pakistan (n 5 196)
Adjusted HR (95% CI)* P Value
Sodiumy 0.94 (0.90e0.97)z !.001
SBPy 0.98 (0.97e0.99)z .016
Pulsey 1.02 (1.01e1.04)z .002
Severe MRx 1.90 (1.03e3.48) .039
Cox model c2 33.7; df 5 4.
HR, hazards ratio; CI, confidence interval; SBP, systolic blood pressure;
Hg, mercury; MR, mitral regurgitation.
*Adjusted for smoking, beta blockers at discharge, angiotensin convert-
ing enzyme inhibitor/angiotensin receptor blocker at discharge, anemia,
troponin elevation, and ejection fraction. HR (95% CI) using categorical
cut points as follows: sodium !135 mmol/L, 2.39 (1.30e4.37); SBP
!100 mm Hg, 2.13 (1.07e4.24); pulse O100/min, 2.28 (1.27e4.08).
yAs recorded on admission.
zFor each unit increase.
xVersus no severe MR.
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worse outcomes in other studies also.15 Consistent with
these findings, b-blockers at discharge was noted to be pro-
tective against mortality on univariate analysis. We found
a relatively high prevalence of severe mitral regurgitation
(30.6%) in our cohort, in line with other data.16 This inde-
pendent relationship of severe mitral regurgitation with
mortality has also been reported elsewhere.17
Our study did not show an independent relationship with
mortality for some factors that deserve mention. LVEF has
been shown to be a strong predictor of mortality in general
with a significant reduction in survival as the LVEF de-
clines from the highest to the lowest quartile. We did not
see such a relationship in our study. One possible reason
is that the LVEF range was fairly narrow (median LVEF
20%, interquartile range 20 to 30), and sample size limita-
tions may not have allowed a relationship between LVEF
and mortality to surface. More important, New York Heart
Association class is a far more robust predictor of out-
come18 and it is possible that the effect of requiring hospi-
talization superseded the differential prognosis that LVEF
may otherwise confer on patients. Clinical trials have
shown that in general, symptomatic patients have modestly
lower LVEFs than asymptomatic patients yet the prognosis
of the former is much worse.19,20 Thus the lack of a relation-
ship between LVEF and mortality in this patient subset is
not entirely surprising. QRS prolongation has been reported
in some series as a predictor of mortality.21 However, our
data did not suggest any difference in outcome between
those with normal and wide QRS complex at presentation.
Diastolic dysfunction, in particular a restrictive mitral
inflow pattern is associated with higher cardiac mortality
in heart failure.22 We saw a trend supporting this associa-
tion but in the multivariable analysis this was not an inde-
pendent predictor, possibly from sample size limitations.
Heart failure from ischemic heart disease tends to have
a worse prognosis than nonischemic cardiomyopathy.23
That ischemic heart was the predominant mechanism of
heart failure in the majority of our patients may have
prevented such a relationship from becoming evident.
Our study is not without limitations. First, this is a single-
center experience and our results may not be extrapolated
to the entire Pakistani population. However, our hospital ca-
ters to a wide mix of patients, ranging from affluent to poor,
somewhat reflective of the population at large. Second, as
discussed previously, ours being a tertiary care center
may have potentially attracted patients with identifiable
(and covert) adverse prognostic features, leading to the ob-
served high mortality. However, we recruited patients with
new-onset heart failure in the hope to avoid such bias. Of
course we cannot distinguish between those patients with
truly new-onset disease and those with undiagnosed heart
failure that led to an admission when the condition wors-
ened. Third, we did not incorporate the effect of revascular-
ization into our predictive model. However, owing to cost
limitations, the majority of patients in this cohort did not
undergo revascularization. Fourth, the effect of compliance
to medical therapy was not assessed in this study. Finally,
because of the retrospective nature of the study several im-
portant variables are missing in our study including reliable
documentation of signs and symptoms as well as anthropo-
metric values. Furthermore, we also do not have outcomes
data on patients admitted for heart failure with preserved
systolic function. We are therefore unable to comment on
any relationship between outcomes and variables such as
obesity in this cohort nor are we able to compare outcomes
of hospitalized heart failure in those with low versus
preserved systolic function.
In conclusion, this is the first report from the Indo-Pakistan
subcontinent on outcomes of patients suffering from sys-
tolic heart failure requiring admission. We report a high
1-year mortality and an even higher combined event rate
(death or hospitalization for heart failure) emphasizing the
highly adverse prognosis of the disease. The number of
patients with systolic heart failure is bound to rise as the
burden of cardiovascular disease in the region continues to
soar. Therefore measures to prevent ischemic heart disease
and its lethal sequelae are essential as developing nations
simply cannot afford to treat and manage heart failure
with their meager health care resources. Further study is
warranted to determine whether the prognosis of Indo-Asian
patients admitted with heart failure but have preserved
systolic function is similarly adverse.
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